NEXGEL, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.0M
- Price
- $0.33
- % Change (Daily % change from the live per-ticker quote feed.)
- -14.79%
- Volume
- 350.7K
About
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
Quick stats
Shares outstanding9.2M
Computed float7.1M
Float / shares76.6%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001468929
Websitehttps://nexgel.com
AI Summary
AI-generated1/10
minormixedearnings
NEXGEL Reports Second Quarter 2026 Financial Results
NexGel reported Q2 revenue of $3.69 million with a net loss of $2.87 million, which included non-recurring charges for amortization and a SilverSeal inventory recall.
Integration of the Celularity acquisition and the BioNX Surgical rollout are progressing slower than anticipated due to supply chain constraints, resulting in a backlog of roughly $795,000.
Shareholders did not approve proposals to increase authorized shares or authorize a reverse stock split due to broker non-votes; management intends to resolicit these proposals in late September.
Red flags
- Integration and revenue ramp progressing slower than anticipated
- Supply chain challenges impacting product availability
- Proxy solicitation failed to approve reverse split authority and increase in authorized shares